Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Elicio Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided updates on its camupepimut clinical program. The company highlighted Phase 2 AMPLIFY-7P data in pancreatic cancer showing a 49% reduction in risk of recurrence or death in ctDNA-negative patients, which will inform its Phase 3 strategy.
“We are excited by the new Phase 2 AMPLIFY-7P findings in adjuvant PDAC, which provide encouraging direction and important insights as we advance camupepimut toward late-stage development and refine our Phase 3 strategy in adjuvant PDAC.”
Robert Connelly, President and Chief Executive Officer
“The 49% lower risk of disease recurrence or death among patients with undetectable ctDNA at baseline, alongside a 43% reduction in risk among ctDNA-positive patients, reinforces the encouraging clinical activity observed across both subgroups.”
Robert Connelly, President and Chief Executive Officer
Karat Packaging reported Q3 2026 net sales of $134.7 million, an 8.2% increase year-over-year, driven by strong e-commerce growth. However, net income fell to $4.7 million from $7.6 million due to pressure from elevated ocean freight costs and resin prices. The company is implementing price increases and diversifying its supply chain to Indonesia and South America to offset these costs.
Term
Q3 2026
“We delivered solid top-line growth in the third quarter, with sales increasing 8.2 percent, and we saw continued strong momentum in our e-commerce business, where online sales grew nearly 38 percent over the prior-year quarter.”
Alan Yu, Chief Executive Officer
“While increased import as well as domestic shipping costs and elevated resin prices pressured margin and contributed to results below our expectations, we remain encouraged by the strength of our sales performance, especially the continued momentum in our e-commerce business expansion.”
Phio Pharmaceuticals reported Q3 2026 financial results, highlighting a cash position of $10.6 million. The company achieved key milestones for its PH-762 program, including the completion of commercial-scale cGMP manufacturing and the submission of Phase 1b clinical data to the FDA in preparation for a Phase 2b study initiation expected in Q1 2027.
Term
Q3 2026
“We have successfully executed on critical development objectives to advance the PH-762 program toward Phase 2b study initiation. Commercial-scale drug substance manufacturing was completed and shipped to our drug product manufacturer in preparation for making clinical trial supply material. We have submitted detailed information to FDA providing final analysis of our Phase 1b clinical trial and the fundamentals of our intended upcoming Phase 2b study.”
Robert J. Bitterman, President and Chief Executive Officer
SiriusPoint reported Q3 2026 net income of $87 million and operating earnings per share of $0.88, representing a 19% increase. The company also announced a loss portfolio transfer (LPT) agreement with RiverStone to exit its remaining run-off reserves, which is expected to unlock over $200 million in capital.
Term
Q3 2026
“Our third quarter results represent continued strong performance, with our diversified, low-volatility portfolio again delivering on both growth and profitability. Our Insurance & Services segment grew by 20% and our core combined ratio was 90.1% both in the quarter and year to date.”
Scott Egan, Chief Executive Officer
“We have also announced another important milestone in the quarter linked to our legacy run-off portfolio, agreeing a loss portfolio transfer with RiverStone. This will allow us to effectively close the door on this historical book of reserves, further simplifying our business and unlocking significant capital.”
Coursera reported a significant revenue increase to $376.7 million for Q3 2026, driven largely by its merger with Udemy, which contributed to a substantial increase in total assets and common stock outstanding. Despite the growth, the company recorded a net loss of $25.6 million for the quarter, impacted by $30.8 million in merger and integration-related costs.
Exzeo Group, Inc. reported net income of $66.0 million for the nine months ended September 30, 2026, compared to $60.8 million in the prior year period. The company maintains a significant concentration of revenue from related parties, primarily HCI Group, Inc., and recently initiated share repurchase programs totaling $37.0 million.
PPG Industries Sr. VP, Perf Coatings Segment Chancey E. Hagerty Sells $318K of Stock
Chancey E. Hagerty, Sr. VP, Perf Coatings Segment, sold 2,500 shares of PPG Industries Inc at $127.14 a share, worth $318K in total on Nov 4, 2026. Shares held after the trade: 9,761 (-20.4%).
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing camupepimut (ELI-002 7P) for adjuvant PDAC and other mKRAS-driven cancers. As of November 3, 2026, the company had 28,307,225 shares of common stock outstanding and is classified as a smaller reporting company and emerging growth company.
Peloton Interactive, Inc. reported its financial results for the first quarter of fiscal 2027, highlighting its ongoing restructuring initiatives and cost-saving measures. As of November 2, 2026, the company had approximately 430 million Class A and 15.8 million Class B shares outstanding, while continuing to focus on achieving future profitability and positive free cash flow.
Phio Pharmaceuticals Corp. reported a net loss of $12.3 million for the nine months ended September 30, 2026, compared to $6.3 million in the prior year period, primarily driven by a significant increase in research and development expenses. As of September 30, 2026, the company held $10.6 million in cash and cash equivalents, down from $21.0 million at the end of 2025.
Universal Electronics Inc. reported financial results for the third quarter ended September 30, 2026, highlighting a significant reduction in GAAP net loss to $0.3 million compared to $8.3 million in the prior year. The company saw strong growth in its connected home segment and generated $16.6 million in operating cash flow through the first nine months of the year.
Vaxart reported third quarter 2026 financial results and provided a business update, highlighting $65.5 million in cash and a runway into Q2 2027. The company expects topline data from its Phase 2b COVID-19 trial, involving approximately 5,400 participants, by mid-year 2027. Additionally, Vaxart expanded its norovirus vaccine IP with a new European patent and appointed Retired Vice Admiral Raquel C. Bono to its Board of Directors.
“During the third quarter, the Vaxart team worked diligently to advance our Phase 2b COVID-19 trial. The release of the topline efficacy and safety data from the main cohort remains a top priority, and we continue to actively work toward completion of analytical testing and disclosure of the trial results, in collaboration with our partner BARDA.”
HA Sustainable Infrastructure Capital Financial Results
HA Sustainable Infrastructure Capital reported Q3 2026 financial results with GAAP EPS of $1.04 and Adjusted EPS of $0.82, representing year-over-year growth. The company reaffirmed its long-term 2028 guidance for Adjusted EPS and ROE while highlighting a 27% increase in managed assets to $19.0 billion.
Term
Q3 2026
“Our team continues to execute on our business plan by adding new clients and deepening our relationships with existing ones, further diversifying into new asset classes, and optimizing our capital platform. These factors have translated into superb financial results through the first three quarters of 2026 with our Managed Assets increasing nearly $3 billion to $19 billion, Adjusted Recurring Net Investment Income growing 23% and Adjusted EPS by 15% year-to-date, and our Adjusted ROE rising to 15.6%.”
Jeffrey A. Lipson, President and Chief Executive Officer
“As much of the global economy has been adjusting to the increase in interest rates over the last few months, HASI continues to demonstrate the benefits of our business model in mitigating the impacts of a higher interest rate environment. Our new asset yields have increased to more than 11% year-to-date and we have continued to maintain our net investment margins. In combination with our growing base of management fees, we are generating greater profitability that is increasingly resilient to changes in the interest rate environment.”
Workiva Inc. reported third quarter 2026 financial results with total revenue of $263 million, a 17% increase year-over-year. The company achieved GAAP net income of $19 million ($0.35 per diluted share) and expanded its non-GAAP operating margin to 18.3% as it continues to leverage AI technology within its audit and compliance platform.
Term
Q3 2026
“AI is fundamentally changing enterprise software, from helping people do the work to increasingly doing the work itself. This shift plays directly to Workiva’s strengths. As software takes on more complex, regulated, and high-stakes work, the need for accuracy, transparency, and trust becomes even more critical. Workiva is uniquely positioned to meet these needs and expand the role our platform plays across the enterprise.”
Julie Iskow, President & Chief Executive Officer
“In Q3, we continued to deliver healthy top-line growth while expanding our operating margins, reinforcing that growth and profitability go hand-in-hand at Workiva. We beat the high end of our revenue guidance with 17% growth in both subscription and total revenue. At the same time, we expanded non-GAAP operating margin by 560 basis points year-over-year.”
The Honest Company reported Q3 2026 financial results, highlighted by 9.2% organic revenue growth and a record underlying adjusted gross margin of 48.9%. The company also announced a new $30 million share repurchase authorization and raised its full-year 2026 financial outlook.
“Our third quarter results demonstrate what a modern personal care company can deliver when the brand, the portfolio, and the P&L are pointed in the same direction. We achieved over 9% Organic Revenue growth and a record Underlying Adjusted Gross Margin of 49%. As a result of our year-to-date performance and a strong roadmap ahead, we are once again raising our full-year outlook. Given our notable margin progress, we are building on our current investments to continue driving brand scale across baby, big kid, and adult households. With a clear strategic vision, a strong financial foundation, and the continued executional discipline of our Honest team, we believe Honest is well positioned to be the most iconic personal care brand of this generation.”
For the nine months ended September 30, 2026, Power Solutions International reported net sales of $483.2 million, a decrease from $531.2 million in the prior year period, while net income significantly improved to $54.1 million. The company highlighted strategic initiatives including its 'Power Boost 2030' strategy and the acquisition of MTL Manufacturing and Equipment.
Unisys Corporation reported a consolidated net loss of $201.0 million for the third quarter of 2026, an improvement from the $308.9 million loss in the prior year period, despite a slight revenue increase to $471.5 million. The company's financial position shows a total stockholders' deficit of $425.1 million as of September 30, 2026, impacted by significant non-cash pension and postretirement adjustments.
Genpact reported Q3 2026 financial results with total revenue growing 7.3% year-over-year to $1.385 billion, driven by 30.3% growth in its Advanced Technology Solutions segment. The company raised its full-year 2026 guidance for gross margin and adjusted diluted EPS following strong execution in its pivot to 'Agentic Operations'.
Term
Q3 2026
“Q3 was another clear proof point that our pivot to Agentic Operations is working, as our flywheel continues to accelerate. Total revenue grew 7.3% year-over-year, and Advanced Technology Solutions revenue growth increased to 30.3%.”
Balkrishan “BK” Kalra, President and CEO, Genpact
“Our Q3 results reflect the strength of our differentiation and execution, with strong revenue growth, significant year-over-year gross margin expansion, and adjusted diluted EPS growth of 10.3%, and we are raising our full year 2026 gross margin and adjusted diluted EPS guidance to reflect this.”
Vanda Pharmaceuticals Director Charles Cliff Duncan Buys $35.2K of Stock
Charles Cliff Duncan, Director, bought 9,250 shares of Vanda Pharmaceuticals Inc. at $3.80 to $3.82 a share (average $3.81) in 2 transactions, worth $35.2K in total between Nov 4, 2026 and Nov 5, 2026. Shares held after the trade: 108,701 (+5.6%).
Prothena reported total revenue of $52.7 million for the first nine months of 2026, driven primarily by $50.1 million from license and intellectual property revenue. The company significantly reduced its operating expenses to $62.6 million compared to $200.1 million in the prior year period, resulting in a narrowed net loss. As of September 30, 2026, the company maintained a cash and cash equivalents balance of $271.4 million.
Citizens, Inc. reported a net income of $1.4 million for the nine months ended September 30, 2026, a decrease from $7.3 million in the prior year period. Total revenues remained relatively stable at $185.2 million, while total stockholders' equity declined to $221.5 million primarily due to unrealized losses on fixed maturity securities.
Clorox Insider Pierre R. Breber Buys $400K of Stock
Pierre R. Breber bought 4,000 shares of Clorox Co at $100.06 a share, worth $400K in total on Nov 4, 2026. Shares held after the trade: 22,000 (+22.2%).
Alarm.com reported Q3 2026 financial results with total revenue increasing 9% year-over-year to $279.4 million, driven by growth in SaaS and license revenue. The company also raised its full-year 2026 SaaS and license revenue guidance to a range of $756.1 million to $756.3 million.
Workiva Inc. reported total revenue of $262.96 million for the third quarter of 2026, a 17.3% increase from the prior year, driven primarily by subscription and support growth. The company achieved a net income of $19.11 million for the quarter, a significant improvement compared to $2.79 million in the same period of 2025.
Halozyme Therapeutics reported strong growth for the third quarter of 2026, with total revenues increasing to $493.0 million compared to $354.3 million in the prior year, driven primarily by higher royalty and product sales. Net income rose to $247.0 million, while the company significantly restructured its debt through the issuance of 2033 Convertible Notes and the repayment of 2027 and 2028 notes.
Five9 reported Q3 2026 revenue of $323.3 million, up 13% year-over-year, and announced a definitive agreement to acquire Level AI for $325 million in cash. The company also provided full-year 2026 revenue guidance of $1.269 billion to $1.275 billion.
Counterparty
Level AI
“Q3 was another solid quarter, highlighted by accelerating subscription revenue growth, with AI revenue growth stepping up significantly. These results indicate that our Humantic CX strategy is working. As AI reshapes the customer experience landscape, we believe adding Level AI strengthens our competitive position, expands the customers we can serve, and deepens the AI talent behind our continuous innovation.”
Keros Therapeutics updated its corporate presentation for use in meetings with investors and analysts. The presentation highlights the company's clinical pipeline, including rinvatercept (KER-065) for Duchenne muscular dystrophy and ALS, and elritercept for myelodysplastic syndromes.
CAMP4 Therapeutics reported third quarter 2026 financial results, ending the period with $124.5 million in cash and cash equivalents. The company received regulatory clearances in the UK and EU to expand its Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder and remains on track to dose the first patient by year-end 2026. Management expects its current cash runway to fund operations through the end of 2028.
“The third quarter was one of continued execution for CAMP4. With regulatory clearances now in place in Australia, Argentina, the United Kingdom, and the European Union, we have launched our first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder.”
Josh Mandel-Brehm, President and Chief Executive Officer
“There are no approved disease-modifying treatments for SYNGAP1, and we are committed to rapidly advancing the development of CMP-002 globally in the hopes of offering SYNGAP1 patients and families a potentially transformative solution that could one day dramatically improve their lives.”
Josh Mandel-Brehm, President and Chief Executive Officer
CVRx reported third quarter 2026 financial results, with total revenue of $13.8 million, a 6% decrease year-over-year. The decline was primarily attributed to lower sales force productivity and challenges with a major payer, though the company expanded its U.S. active implanting centers to 262.
“While we recognize there is more work ahead, we remain encouraged by the progress we are making on key strategic initiatives, including the expansion of Medicare Advantage coverage and the clinical evidence released at HFSA. With new Medicare Advantage coverage policies, BENEFIT-HF enrolling, and continued focus on commercial execution, we are confident in our ability to bring this therapy to more patients living with heart failure.”
Kevin Hykes, President and Chief Executive Officer of CVRx
Fate Therapeutics entered into a sales agreement with Leerink Partners to establish an at-the-market (ATM) offering program for up to $100 million of its common stock. The company is not obligated to sell any shares and will pay a commission of up to 3.0% on any gross proceeds. This program replaces a previous ATM facility that was terminated concurrently.